Functional decline in Huntington's disease. - Wikidata - wikimedia - TriplyDB

Functional decline in Huntington's disease.

Functional decline in Huntington's disease.

http://www.wikidata.org/entity/Q45288490

about

Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.Thalamic metabolism and symptom onset in preclinical Huntington's disease.Effect of tetrabenazine on motor function in patients with huntington disease.Differences in duration of Huntington's disease based on age at onset.How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease.Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study A systematic review of the treatment studies in Huntington's disease since 1990.Symptomatic treatment of Huntington disease Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia Body weight is a robust predictor of clinical progression in Huntington disease.Rate of change in early Huntington's disease: a clinicometric analysis.Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study.Striatal hypometabolism in premanifest and manifest Huntington's disease patients.Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease.Riluzole therapy in Huntington's disease (HD).Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.Clinical characterization of dystonia in adult patients with Huntington's disease.Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease.Age, CAG repeat length, and clinical progression in Huntington's disease.The association between chronic illness and functional change among participants in a comprehensive geriatric assessment program.Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification

P2860

Q28538703-9EC66B1C-B8C7-4A0E-97E8-45F3DE2D2918 Q33922831-E418E5CA-E15C-44A3-B177-6AA56F113A33 Q34624765-5AFD380D-4F2D-4C97-9798-8B5776761AAC Q34692568-777AA624-4555-45EE-9D5F-3AE2240B7AD3 Q35309355-98196713-96FD-4804-A7AB-8474249C0515 Q35449269-CD6631E1-68A2-4048-A0E0-7ED1855B52A0 Q35880816-BAE639FE-E7BF-4A4C-BC82-6AE10C47E80F Q36045301-611F9267-C7C6-45D3-9E0E-9AC2A5199B9B Q36316928-7FDD9D21-07ED-44B6-8CAC-59E5C8054154 Q36719669-C5118B54-DB38-4DCB-9C42-0A273E4C93FF Q37131233-2C2EBAD2-001D-415B-9862-566A613F1847 Q37265881-72697766-021C-49DA-B20B-F2FA4A0842CA Q38639328-F5BE9475-2EDC-4234-B7B6-DD64D6A0A7C9 Q39685633-454F6EE4-8E1F-47C5-BD5B-6D6856E4302A Q45062996-2C259FE1-AFA7-4739-94F0-18CD233D3EDE Q45292050-8DA8EA64-0A30-4106-9E70-4F010F3F2BCB Q45295893-5E0B1ED2-72B0-4FF7-BCDF-87999B5A3D2F Q45297529-68BF58A2-C71B-4957-8F2C-F28D1C2DA63A Q45297539-A565EB2F-168A-4F9D-922D-9D3B8B474253 Q45300446-0215FFEB-3604-4EFE-B578-7BC44DE82E21 Q45302935-4EA43410-F157-4237-8642-ADE599D30C9D Q45303096-B9B2C23F-3850-49F1-98DF-8C48913E21FB Q45305597-BBFC574C-358E-4D31-968D-A8151D82774D Q46186103-BF37F84C-C2B7-4D01-A1A8-353B402DFEE4 Q47694898-6E14BC7C-AA43-445F-AC36-3882D4A017C2 Q58574520-FCA0F818-1491-448E-BC3F-F7C5CE52847D Q58574973-16F22345-83A1-4283-A86D-F8402010060A

P2860

Functional decline in Huntington's disease.

http://www.wikidata.org/entity/Q45288490

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年学术文章

@wuu

1995年学术文章

@zh

1995年学术文章

@zh-cn

1995年学术文章

@zh-hans

1995年学术文章

@zh-my

1995年学术文章

@zh-sg

1995年學術文章

@yue

1995年學術文章

@zh-hant

name

Functional decline in Huntington's disease.

@en

Functional decline in Huntington's disease.

@nl

type

label

Functional decline in Huntington's disease.

@en

Functional decline in Huntington's disease.

@nl

prefLabel

Functional decline in Huntington's disease.

@en

Functional decline in Huntington's disease.

@nl

P1433

Q45288490-C915FD70-DE2F-46A5-BD0E-E6DEDEA8812C

P1476

Q45288490-AC451948-6A4F-4AE8-AA5B-B14E5C2F56A1

P2093

Q45288490-003BEAAE-6524-4969-89CE-0B45BBCFB4F8

Q45288490-05BA57EC-8E1D-4711-9B79-C5C49E215499

Q45288490-0C9FCDBB-C99F-454F-B704-13F6440127D3

Q45288490-2037F7A8-FC35-4FDF-969C-C8E64BFED6C0

Q45288490-3868181E-B431-4D5B-A9C9-CE1A098CE4DF

Q45288490-3D89BD0C-2A2E-45A9-9EE5-7EC53AE9013F

Q45288490-53EF5A72-A284-46C2-8E36-8B0D42656FEA

Q45288490-76C87A33-0FDD-48DB-A943-7AACBCE0FAC4

Q45288490-CE490CA3-EB13-4F23-A020-3F8B4BFA30EB

Q45288490-F9FE557E-08FF-4417-81D4-5777587BA4AC

P2860

Q45288490-31AE6A34-D9CF-409C-88D1-875F3238C38E

Q45288490-3391DBBE-D3AB-4AC2-9AA3-4585AC81D8A3

Q45288490-69861DA0-9D5C-4510-9DBF-27C44F0324B2

Q45288490-73E9FAAA-A31C-462E-916B-CB82D523F98C

Q45288490-AC17F028-C3D7-4715-8841-8AE99B1903FE

P304

Q45288490-3D546CE3-507E-4A49-9354-116F49731A2B

P31

Q45288490-ADB32382-3445-4B41-96B1-4B187FD780A7

P356

Q45288490-803BAA87-0F14-45A1-BF23-B1ED6B5624F1

P407

Q45288490-17130329-3CD0-4D5E-8EC7-F95A4C964E9A

P433

Q45288490-981E316F-11D6-4AFE-A265-8DAE2D7A583B

P478

Q45288490-511C6AF5-DB28-400F-9183-A1BA845DF14C

P577

Q45288490-6D94848C-14A5-42F0-8552-B716C42AD7F8

P698

Q45288490-D6E4D802-2035-496D-B5F0-2169AC77FB36

P921

Q45288490-7A59D7C6-C5B6-40FC-85DB-45B05CB7EB47

P356

P1433

Movement Disorders

P1476

Functional decline in Huntington's disease.

@en

P2093

Bordwell K

http://www.w3.org/2001/XMLSchema#string

Como P

http://www.w3.org/2001/XMLSchema#string

Feigin A

http://www.w3.org/2001/XMLSchema#string

Hickey C

http://www.w3.org/2001/XMLSchema#string

Kieburtz K

http://www.w3.org/2001/XMLSchema#string

Orme C

http://www.w3.org/2001/XMLSchema#string

Shoulson I

http://www.w3.org/2001/XMLSchema#string

Sotack J

http://www.w3.org/2001/XMLSchema#string

Steinberg K

http://www.w3.org/2001/XMLSchema#string

Zimmerman C

http://www.w3.org/2001/XMLSchema#string

P2860

Factors associated with slow progression in Huntington's disease.

CAG repeat size and clinical presentation in Huntington's disease.

Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs.

Psychiatric syndromes in Huntington's disease.

P304

211-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.870100213

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

1995-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7753064

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease